Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of SHR0410 in Healthy Male Participants
NCT03493191Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Apr 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of riminkefon in acute pain (7 arms), sponsored by Atridia Pty Ltd. Primary endpoints: Incidence of Adverse events in terms of changes in Hematology, Incidence of Adverse events in terms of changes in Urinalysis and 4 more. Started Apr 2018; status: completed.
02
Drugs
riminkefon
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT03493191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493191.